Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar;28(3):472-476.
doi: 10.1038/s41591-022-01700-x. Epub 2022 Jan 14.

Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant

Yu Gao #  1 , Curtis Cai #  1 , Alba Grifoni  2 , Thomas R Müller  1 , Julia Niessl  1 , Anna Olofsson  3 , Marion Humbert  3 , Lotta Hansson  4   5 , Anders Österborg  4   5 , Peter Bergman  3   6 , Puran Chen  1 , Annika Olsson  6 , Johan K Sandberg  1 , Daniela Weiskopf  2 , David A Price  7   8 , Hans-Gustaf Ljunggren  1 , Annika C Karlsson  3 , Alessandro Sette  2   9 , Soo Aleman  6   10 , Marcus Buggert  11
Affiliations

Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant

Yu Gao et al. Nat Med. 2022 Mar.

Abstract

The emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron (B.1.1.529) variant of concern (VOC) has destabilized global efforts to control the impact of coronavirus disease 2019 (COVID-19). Recent data have suggested that B.1.1.529 can readily infect people with naturally acquired or vaccine-induced immunity, facilitated in some cases by viral escape from antibodies that neutralize ancestral SARS-CoV-2. However, severe disease appears to be relatively uncommon in such individuals, highlighting a potential role for other components of the adaptive immune system. We report here that SARS-CoV-2 spike-specific CD4+ and CD8+ T cells induced by prior infection or BNT162b2 vaccination provide extensive immune coverage against B.1.1.529. The median relative frequencies of SARS-CoV-2 spike-specific CD4+ T cells that cross-recognized B.1.1.529 in previously infected or BNT162b2-vaccinated individuals were 84% and 91%, respectively, and the corresponding median relative frequencies for SARS-CoV-2 spike-specific CD8+ T cells were 70% and 92%, respectively. Pairwise comparisons across groups further revealed that SARS-CoV-2 spike-reactive CD4+ and CD8+ T cells were functionally and phenotypically similar in response to the ancestral strain or B.1.1.529. Collectively, our data indicate that established SARS-CoV-2 spike-specific CD4+ and CD8+ T cell responses, especially after BNT162b2 vaccination, remain largely intact against B.1.1.529.

PubMed Disclaimer

Conflict of interest statement

A.S. is a consultant for Gritstone Bio, Flow Pharma, Arcturus Therapeutics, ImmunoScape, CellCarta, Avalia, Moderna, Fortress and Repertoire, and the La Jolla Institute has filed patents to protect various aspects of the T cell epitope and vaccine design work. S.A. has received honoraria from Gilead, AbbVie, MSD and Biogen and research grants from Gilead and AbbVie. M.B. is a consultant for Oxford Immunotec. The other authors declare no conflicts of interest.

Figures

Fig. 1
Fig. 1. Cross-reactive CD4+ T cell responses against B.1.1.529.
a, Representative flow cytometry plots showing spike-specific CD4+ T cell responses (CD69+CD154+) to peptide pools representing wild-type SARS-CoV-2 (WT) or B.1.1.529. b, Frequencies of all spike-specific CD4+ T cells in BNT162b2-vaccinated, convalescent and seronegative individuals. Numbers indicate median reduction in the frequency of detected responses. Comparisons used two-sided Wilcoxon signed rank tests. *P = 0.012. c, Stimulation indices calculated as fold change in frequency relative to the negative control. Numbers indicate the percentage of individuals with a detectable response. d, Cross-reactive responses depicted on an individual basis as percentage B.1.1.529/wild-type. e, Helper polarization of spike-specific CD4+ T cells with representative gating and dot plots showing the distribution of subsets across individuals with detectable responses. Pie charts show the mean frequency of each subset across all individuals in each group. f, Canonical memory differentiation profiles of spike-specific CD4+ T cells with representative gating and dot plots showing the distribution of subsets across individuals with detectable responses. g, Functional profiles of spike-specific CD4+ T cell responses in BNT162b2-vaccinated individuals with representative gating and pie charts showing the mean frequency for each combination. Polyfunctional responses were compared using a permutation test. Data in dot plots are shown as median ± interquartile range. Each dot represents one donor.
Fig. 2
Fig. 2. Cross-reactive CD8+ T cell responses against B.1.1.529.
a, Representative flow cytometry plots showing spike-specific CD8+ T cell responses (CD69+CD137+) to peptide pools representing wild-type SARS-CoV-2 (WT) or B.1.1.529. b, Frequencies of all spike-specific CD8+ T cells in BNT162b2-vaccinated, convalescent and seronegative individuals. Numbers indicate median reduction in the frequency of detected responses. Comparisons used two-sided Wilcoxon signed rank tests. c, Stimulation indices calculated as fold change in frequency relative to the negative control. Numbers indicate the percentage of individuals with a detectable response. d, Cross-reactive responses depicted on an individual basis as percentage B.1.1.529/wild-type. e, Canonical memory differentiation profiles of spike-specific CD8+ T cells with representative gating and dot plots showing the distribution of subsets across individuals with detectable responses. f, Functional profiles of spike-specific CD8+ T cells in BNT162b2-vaccinated individuals with representative gating and pie charts showing the mean frequency for each combination. Polyfunctional responses were compared using a permutation test. Data in bar charts are shown as mean ± 95% confidence intervals, and data in dot plots are shown as median ± interquartile range. Each dot represents one donor. GrzB, granzyme B; NS, not significant.
Extended Data Fig. 1
Extended Data Fig. 1. Peptide validation experiments.
a, Representative flow cytometry plots showing the gating strategy used to assess spike-specific CD4+ and CD8+ T cell responses to peptide pools representing wild-type SARS-CoV-2 (WT) or B.1.1.529. b,c, Frequencies of spike-specific CD4+ (b) and CD8+ T cells (c) in BNT162b2-vaccinated individuals, comparing test 15mer peptide pools versus validation 20mer peptide pools representing wild-type SARS-CoV-2 (WT) or B.1.1.529. d, Pairwise analysis of spike-specific CD4+ (red lines) and CD8+ T cell responses (blue lines) in BNT162b2-vaccinated and convalescent individuals. Data in dot plots are shown as median ± IQR. Each dot represents one donor. **P = 0.007 (Two-sided Wilcoxon signed rank test). ns, not significant.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Dyer O. COVID-19: Omicron is causing more infections but fewer hospital admissions than delta, South African data show. BMJ. 2021;375:n3104. doi: 10.1136/bmj.n3104. - DOI - PubMed
    1. Cameroni, E. et al. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature10.1038/s41586-021-04386-2 (2021). - PMC - PubMed
    1. Liu L. et al. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature10.1038/s41586-021-04388-0 (2021). - PubMed
    1. Collie, S., Champion, J., Moultrie, H., Bekker, L. G. & Gray, G. Effectiveness of BNT162b2 vaccine against Omicron variant in South Africa. N. Engl. J. Med. 10.1056/NEJMc2119270 (2021). - PMC - PubMed
    1. Goga, A., et al. Breakthrough COVID-19 infections during periods of circulating Beta, Delta and Omicron variants of concern, among health care workers in the Sisonke Ad26.COV2.S vaccine trial, South Africa. Preprint at medRxiv10.1101/2021.12.21.21268171 (2021).

Publication types

Supplementary concepts